Investment treaty disputes in the life sciences Industry
In its global scale and economic impact, the life sciences industry presents unique considerations for investment treaty arbitrations. The covid-19 pandemic...
CRA’s life sciences arbitration support is grounded in a comprehensive, insiders’ understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 25 years, we have consulted directly with major life science companies, law firms, and regulatory agencies around the globe. This deep industry knowledge is complemented by our extensive experience in complex litigation. CRA’s involvement has helped our clients solve their most challenging strategic problems and resolve their most contentious disputes.
Engagements
- 01Breach of a global co-marketing deal: Swiss arbitrationSituation: Our client, a major pharmaceutical manufacturer, had to prove damages from the wrongful termination of its global co-marketing/co-promotion rights...View engagement
- 02AAA arbitration regarding a collaboration and license agreementCRA provided expert reports and testimony on behalf of the respondent in an AAA arbitration concerning the “fair market value” of rights exchanged in later...View engagement
- 03AAA arbitration regarding breach of purchase agreementCRA was retained by the claimant in a dispute at AAA alleging breach of a purchase agreement due to the respondent’s alleged failure to make contracted minimum...View engagement
Meet our team
![Gregory Bell | Expert Witness | Charles River Associates]()
Gregory K. BellGroup Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.com![]()
![Peter Rankin Life Sciences Litigation Charles River Associates]()
![Andrew Tepperman | Life Sciences Litigation | Charles River Associates]()